BMS launches dual immunotherapy for metastatic melanoma
Bristol Myers Squibb (BMS) has announced the launch of RELOPDUO, a fixed-dose combination of nivolumab and relatlimab) in India following approval from the Central Drugs Standard Control Organisation (CDSCO).The company said the therapy is India’s first LAG-3-based dual…
- ▪Bristol Myers Squibb (BMS) has announced the launch of RELOPDUO, a fixed-dose combination of nivolumab and relatlimab) in India following approval from the Central Drugs Standard Control Organisation (CDSCO).The company said the therapy is
The Hindu — Top publishes from India and files mainly under world. We currently carry 7,593 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Hindu — Top |
| Canonical URL | https://www.thehindu.com/sci-tech/health/bms-launches-dual-immunotherapy-for-metastatic-melanoma/article71271835.ece |
| Publication time | Mon, 27 Jul 2026 15:59:53 +0530 |
| Retrieval time | 2026-07-27T10:36:11.316Z |
| Last seen | 2026-07-27T10:36:11.316Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | PfpRlGquVsn8 · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Bristol Myers Squibb (BMS) has announced the launch of RELOPDUO, a fixed-dose combination of nivolumab and relatlimab) in India following approval from the Central Drugs Standard Control Organisation (CDSCO).The company said the therapy is India’s first LAG-3-based dual immunotherapy and is indicated for adults and children aged 12 years and above with unresectable or metastatic melanoma. RELOPDUO combines the PD-1 inhibitor nivolumab with the LAG-3 inhibitor relatlimab to target two immune checkpoints involved in the body’s immune response against cancer.According to BMS, the approval is supported by findings from the Phase 2/3 RELATIVITY-047 trial, which showed improved progression-free survival compared with nivolumab alone.
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu — Top.
Discussion
0 commentsMore from The Hindu — Top
